GIPAM GmbH and Inka Health announce their partnership to Advance HEOR and Regulatory Science through Enhanced Real-World Evidence and Analytics

GIPAM GmbH and Inka Health are thrilled to announce their partnership. This collaboration is poised to set new benchmarks in the generation of real-world evidence (RWE) and the application of advanced analytics across the healthcare sector. Through this partnership, GIPAM and Inka Health are committed to providing collaborators with unmatched support in HEOR and regulatory science, marking a significant advancement in the field and setting a new standard for excellence in healthcare research.

GIPAM is acclaimed for its unparalleled access to high-quality European and US real-world data and its proficiency in executing multi-country retrospective database studies. With advanced analytical capabilities, GIPAM offers a solid foundation for evidence generation and evidence synthesis in various therapeutic domains, including the areas of rare diseases and complex treatment scenarios, and dedicated strategic market access expertise support.

Inka Health, brings to the table its specialized expertise in advanced analytics, notably in indirect treatment comparisons and real-world oncology evidence generation as well as experience in the realm of Canadian data sources. The team's experience in methods such as target trial emulation complements GIPAM's comprehensive services, creating a synergy that enhances the value offered to collaborators.

“The partnership between GIPAM and Inka Health is a strategic collaboration that merges GIPAM's extensive European data access and analytical expertise with Inka Health's innovative approach to analytics and evidence generation,” said Paul Arora, CEO of Inka Health. This collaboration is designed to deliver end-to-end RWE solutions, empowering collaborators to navigate the complexities of the regulatory landscape effectively.

“The joint efforts of GIPAM and Inka Health will ensure that research conducted under this partnership is not only scientifically robust but also strategically positioned to influence healthcare decision-making on a global scale” said Thomas Wilke, Managing Partner at GIPAM .